Skip to main navigation Skip to search Skip to main content

Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds

  • C4591007 Clinical Trial Group

Research output: Contribution to journal › Article › peer-review

7   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science